Podcasts

Episode 1 | Improving Survival In Oncogene Driven Lung Cancer

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Improving Survival In Oncogene Driven Lung Cancer

Episode Summary

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Prof Ben Solomon & A/Prof Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.

Show Hosts

This episode’s host are:

  • Prof Ben Solomon, Scientific Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer
  • A/Prof Thomas John, Scientific Committee Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer Centre

Play Episode 1 | Improving Survival In Oncogene Driven Lung Cancer

More Podcasts

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and
In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'
Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining